526 related articles for article (PubMed ID: 20460163)
1. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
[TBL] [Abstract][Full Text] [Related]
8. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
9. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
Kubiak DW; Koo S; Hammond SP; Armand P; Baden LR; Antin JH; Marty FM
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1462-5. PubMed ID: 22564264
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole: an oral triazole with an extended spectrum of activity.
Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
13. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
14. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
17. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
18. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
19. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
[TBL] [Abstract][Full Text] [Related]
20. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]